Colorectal/breast cancer
Conditions
Interventions
Experimental group:Patients with locally advanced and end-stage solid tumors who have received prior platinum-based or paclitaxel-based regimens will receive three cycles of front-line therapy with co
Sponsors
South China Hospital of Shenzhen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: All enrolled subjects must meet all of the following criteria in order to be included in this study: 1) Patients diagnosed as unresectable local advanced or end-stage solid tumors, such as colorectal cancer, breast cancer, etc; 2) Age range: 18-75 years old; 3) ECOG score 0-1 points; 4) Previous use of multi line chemotherapy regimen, assessed as SD or PD, does not rule out the possibility of concomitant use of ADC and immune checkpoint inhibitors; 5) After communication, they are willing to participate in this trial, promise to take medication as prescribed by the doctor, and can follow up and communicate on time.
Exclusion criteria
Exclusion criteria: Any candidate subject who meets any of the following criteria will not be enrolled in this study: 1) Any of the following circumstances: people with immune deficiency or impairment (such as AIDS patients), who are using immunosuppressive drugs or radiotherapy; Patients with fever and acute infectious diseases, including active tuberculosis, or those receiving anti tuberculosis treatment; Accompanied by severe chronic cardiovascular and cerebrovascular diseases or chronic kidney disease; 2) Merge with other tumors; 3) Known to have low immune function, acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 4) Suffering from serious cardiovascular and cerebrovascular diseases, such as myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accidents or transient ischemic attacks, or pulmonary embolism; 5) There are obvious dysfunction of major internal organs, such as creatinine>2 times the upper limit of the normal range, ASTALT Total bilirubin>2 times the upper limit of the normal range, etc; 6) Subjects with fever and body temperature exceeding 38 ?, as well as active infections such as acute pneumonia, active tuberculosis, and severe urinary tract infections that may affect clinical trials; 7) Researchers believe that there may be any situation that increases the risk to participants or interferes with the execution of clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactLi Yuqing
South China Hospital of Shenzhen University
Outcome results
None listed